Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390

Benzinga Newsdesk www.benzinga.com Positive 76.7%

Neg 0% Neu 0% Pos 76.7%

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $350 to $390.